A real-world analysis found BRAF V600E-mutated papillary thyroid cancer had a proinflammatory molecular profile, but no significant overall survival difference versus BRAF wild-type disease. Treatment choice among BRAF/MEK inhibitors, tyrosine kinase inhibitors, and immunotherapy was not associated with significant survival differences.
Hanmi Pharmaceutical has initiated phase 2 patient dosing of belvarafenib for NRAS-mutated melanoma in Korea, enrolling the first patient at a university hospital. The multicenter trial will evaluate combination therapy in 45 patients with locally advanced or metastatic disease.
Liquid biopsy-based circulating tumour DNA analysis has evolved from single-gene testing to comprehensive genomic profiling, enabling detection of actionable targets and minimal residual disease in colorectal cancer patients.
Relay Therapeutics reported full-year 2025 revenue of $15.36 million and a narrowed net loss of $276.48 million, while securing FDA Breakthrough Therapy designation for lead asset zovegalisib. The company filed a $96.18 million shelf registration.
Phase 2 SWOG S1512 trial shows neoadjuvant pembrolizumab achieved 71% pathologic complete response in resectable desmoplastic melanoma with 3-year survival rates of 74% for relapse-free and 87% for overall survival.
New combination therapies demonstrate improved outcomes in advanced anal and colorectal cancers, with retifanlimab plus chemotherapy approved for anal cancer and onvansertib showing strong efficacy signals in RAS-mutated colorectal cancer.
